NCT05667116View on ClinicalTrials.gov

eVusheld Assessment reaL wORld Effectiveness at UPMC

CompletedOBSERVATIONAL

Enrollment

4,232

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

July 24, 2023

Study Completion Date

July 24, 2023

Conditions

SARS-CoV-2, COVID-19

Interventions

DRUG

EVUSHELD

EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)

Trial Locations (1)

15213

Research Site, Pittsburgh

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

University of Pittsburgh

OTHER

lead

AstraZeneca

INDUSTRY